We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Institute for Clinical and Economic Review (ICER) released an updated draft report on the cost-effectiveness of rheumatoid arthritis treatments but the new approach did not change the overall findings. Read More
Doctors Without Borders called on Johnson & Johnson to lower the cost of its anti-tuberculosis drug bedaquiline to $1 or less per day and allow other drugmakers to make generic versions. Read More
A New Jersey court threw out a proposed class action lawsuit against Johnson & Johnson and Actavis that accused them of causing inflated insurance premiums through their actions in the opioid crisis. Read More
The U.S. Federal Court of Appeals upheld a lower court ruling that bars Actavis’ generic of the osteoarthritis cream Pennsaid (diclofenac) two percent formulation until 2027. Read More
The agency said the testimonials do not “adequately support the suggestion in the presentation that other patients switching to Livalo from other statins will experience a similar reduction in side effects.” Read More
Impax Laboratories has sued the Federal Trade Commission for improperly deciding that it’s 2010 settlement with Endo Pharmaceuticals over Opana ER (oxycodone extended release) was anticompetitive. Read More
The U.S. Sixth Circuit Court of Appeals threw out Ohio Attorney General Dave Yost’s attempt to stop the Oct. 21 opioid bellwether trial of two Ohio counties against drugmakers and distributors. Read More
The company was accused of paying kickbacks to patients by covering patient copayments regardless of financial need and paying telemedicine physicians to write prescriptions without a legitimate prescriber-patient relationship. Read More